THRB and metabolic dysfunction-associated steatohepatitis: For example, Resmetirom (MGL-3196), a THRβ agonist, significantly improved hepatic steatosis in NASH patients and ameliorated the progression of liver fibrosis in mice with advanced NASH without affecting body weight [46, 47].